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Maintenance of Sinus Rhythm
in Patients With Atrial Fibrillation
An AFFIRM Substudy of the First Antiarrhythmic Drug
The AFFIRM First Antiarrhythmic Drug Substudy Investigators
OBJECTIVES This study evaluated the efficacy of antiarrhythmic drugs for the treatment of atrial fibrillation
(AF).
BACKGROUND The most effective and safest antiarrhythmic drug for the treatment of AF is unknown.
METHODS The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study
compared two treatment strategies—rate control and rhythm control—in patients with AF
and risk factors for stroke or death. This substudy, performed in patients randomized to
rhythm control, compared different antiarrhythmic drugs by randomly assigning the first drug
treatment to: 1) amiodarone, 2) sotalol, or 3) a class I drug. The primary end point was the
proportion of patients alive, in sinus rhythm, with no additional cardioversions and still taking
the assigned drug at one year. Comparisons were made between patients eligible for each of
three drug pairs.
RESULTS At one year, in 222 patients randomized between amiodarone and class I agents, 62% were
successfully treated with amiodarone, compared with 23% taking class I agents (p  0.001).
In 256 patients randomized between amiodarone and sotalol, 60% versus 38% were
successfully treated, respectively (p 0.002). In 183 patients randomized between sotalol and
class I agents, 34% versus 23% were successfully treated, respectively (p  0.488), although
this portion of the substudy was stopped early when amiodarone was shown to be better than
class I agents. Sinus rhythm was achieved in nearly 80% of patients at one-year follow-up with
serial therapy. Adverse effects were common.
CONCLUSIONS Amiodarone was more effective at one year than either sotalol or class I agents for the strategy
of maintenance of sinus rhythm without cardioversion. (J Am Coll Cardiol 2003;42:20–9)
© 2003 by the American College of Cardiology Foundation
The most effective and safest antiarrhythmic drug for the
maintenance of sinus rhythm in patients with atrial fibril-
lation (AF) remains uncertain. Rhythm control of AF using
antiarrhythmic drug therapy in some patients might offer
clinically meaningful advantages, such as increased exercise
tolerance, decreased symptoms, and prevention of atrial
remodeling (1,2). Studies of a host of antiarrhythmic agents
administered to maintain sinus rhythm in patients with AF
have been previously reported (3–5). Efficacy rates in main-
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taining sinus rhythm have been variably defined in diverse
AF populations and approximate 50% at one year. Recent
meta-analyses have emphasized that few studies have long-
term follow-up, that most do not report meaningful mor-
tality statistics, and that a clear superiority of one drug over
another has not been demonstrated (4,5). All antiarrhyth-
mic agents have the potential for serious or even lethal
adverse events, which are seen more commonly in patients
with left ventricular dysfunction, congestive heart failure, or
ischemic heart disease (6–10).
The Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) study was a randomized
clinical trial in patients with AF and a high risk of stroke or
death, comparing two treatment strategies: 1) attempting to
maintain sinus rhythm, principally with antiarrhythmic
drugs (“rhythm control”); and 2) allowing AF to persist or
recur while controlling the ventricular rate, principally with
atrioventricular node blocking drugs (“rate control”) (11–
13). Both arms of the study utilized anticoagulation. In the
population studied, it was shown that rhythm control
offered no advantage over rate control. In the group of
patients assigned to the rhythm control strategy in
AFFIRM, a substudy conducted at 80 of the 213 clinical
sites compared the ability of different antiarrhythmic drugs
to maintain sinus rhythm at one year by randomly assigning
therapy to either amiodarone, sotalol, or a class I drug.
METHODS
The AFFIRM study evaluated 4,060 patients recruited at
213 clinical sites in the U.S. and Canada from November
1995 through October 1999 (11–13). The study was ap-
proved by each site’s Institutional Review Board, and all
patients gave written, informed consent. The primary end
point for the main study was death from any cause.
Follow-up in the main study and this substudy ended on
October 31, 2001 (13).
The First Antiarrhythmic Drug Substudy. This substudy
was a second randomization of patients assigned to the
rhythm control arm of AFFIRM, performed at 80 study
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sites (11,12). Patients had to be eligible to receive treat-
ment randomized from at least two of the three antiarrhyth-
mic drug choices: amiodarone, sotalol, or a class I agent
(Table 1). Patients previously failing one class I drug were
not necessarily excluded from receiving a different class I
drug, unless the patient had experienced torsade de pointes
ventricular tachycardia as the reason for the intolerance of
the first class I drug. All eligibility decisions were made by
the enrolling physician, in discussion with the patient.
Although a patient might not have met any strict criteria for
contraindications for a drug, that drug might have been
eliminated from consideration for many reasons. For exam-
ple, if quinidine had been associated with unacceptable
diarrhea and had not been effective at that dose, it would not
have been used again. Likewise, some patients may have had
such severe lung disease that the physician may have been
unwilling to use amiodarone. As a registry was not kept
either for the main trial or for this substudy, we do not know
how many patients were considered for enrollment in the
First Antiarrhythmic Drug Substudy, the reasons that some
patients were eliminated from consideration, or the precise
reasons that some drugs were considered to be inappropriate
for the substudy.
At the time of the randomization telephone call to the
Clinical Trial Center, the investigator reported whether the
patient was eligible and agreed to randomization in the First
Antiarrhythmic Drug Substudy. Patients randomized to the
rhythm control arm of the main AFFIRM study then
received a second randomization of the antiarrhythmic drug
to be used in this substudy.
The substudy was designed to be three separate compar-
isons between two drugs: amiodarone versus class I agents,
amiodarone versus sotalol, and sotalol versus class I agents.
If a patient was eligible for all three drug arms, the
randomization was performed among all three drug groups,
and the patient’s data were added to the pool of data in two
two-way comparisons. For example, a patient eligible for
amiodarone, sotalol, and a class I agent might be random-
ized to amiodarone. His or her data would be included in
the amiodarone arm of both the amiodarone versus class I
comparison and in the amiodarone versus sotalol compari-
son. Thus, a patient may be represented in more than one
two-way comparison, and the sum of patients in all six arms
of the three two-way comparisons would exceed the total
number of patients participating in the substudy. A patient
Table 1. Antiarrhythmic Drug Use
Drug Starting Dose
Minimum
Maintenance
Dose Precautions† Contraindications‡
Amiodarone 10 g over 1 week 200 mg/day*
Sotalol 160 mg/day 240 mg/day Asthma, renal dysfunction
requiring dialysis, current
CHF class II, history of
CHF and LVEF 0.30 or
LVEF 25 alone
Class I agent Left ventricular dysfunction (CHF,
low LVEF); ischemic heart disease
Quinidine 600 mg/day
Procainamide 1,500 mg/day Blood counts every week for 12 weeks and
as needed thereafter; blood tests for
lupus syndrome every 3–6 months
Disopyramide 300 mg/day LVEF 0.30
Moricizine 400 mg/day
Class I-C agent Required for use of class I agents:
normal LV, normal stress test
CHF, structural heart disease,
myocardial disease, LVH,
CAD, abnormal LV
function/wall motion,
LVEF 0.50
Propafenone 450 mg/day
Flecainide 100 mg/day
*A dose of 100 mg/day could be used if adverse effects required a lower dose, and higher doses (up to 400 mg/day) could be used, as necessary. †General precautions to be observed
in the first antiarrhythmic drug substudy: careful monitoring for proarrhythmia, bradycardia, and hypokalemia; caution for the negative inotropic effects of drugs; corrected QT
interval. (QTc) must not exceed 0.52 s after drug titration; particular caution in patients with LVH or organic heart disease; atrioventricular node blocking drugs to be given as
appropriate; and monitoring for renal and hepatic dysfunction in the elderly. ‡Any drug associated with prior inefficacy, intolerable adverse effects, or torsade de pointes could
not be used again. General contraindications to inclusion in the first antiarrhythmic drug substudy: long QT at baseline (QTc 0.46 s).
CAD coronary artery disease; CHF  congestive heart failure; LV  left ventricular; LVEF left ventricular ejection fraction; LVH  left ventricular hypertrophy; Stress
test  evaluation for stress-induced ischemia (exercise test, stress thallium or sestamibi, stress echocardiogram, pharmacologic stress radionuclide scan, or pharmacologic stress
echocardiogram); alternatively, a normal coronary angiogram could substitute for the stress test.
Abbreviations and Acronyms
AF  atrial fibrillation
AFFIRM  Atrial Fibrillation Follow-up Investigation
of Rhythm Management
ECG  electrocardiogram/electrocardiographic
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eligible for only two drug arms would be randomized
between those two arms and his or her data included only in
that single two-way comparison.
Although amiodarone could be administered as a low
dose (200 mg/day) or high dose (400 mg/day), it counted as
only a single drug for this substudy analysis. If patients were
assigned to a class I drug, the choice among available class
I drugs was made by the treating physician. If the patient or
physician declined participation in this substudy, the choice
of antiarrhythmic drug for the main study was then made by
the physician.
Recurrence of AF while on the first antiarrhythmic drug,
followed by spontaneous reversion to sinus rhythm, did not
constitute a drug failure. However, it is likely that the drug
would have been discontinued and thus considered to be a
failure if the patient had severe symptoms with the recur-
rence. Recurrence of AF while on the first antiarrhythmic
drug without spontaneous reversion to sinus rhythm was
classified as a drug failure for the purposes of this substudy.
Discontinuation of the first class I drug, with substitution of
another class I drug, was also considered to be a failure.
However, the main AFFIRM protocol encouraged contin-
ued use of the drug in the presence of only one such
“failure.” Any subsequent drug choice was left to the
discretion of the investigator.
Antiarrhythmic drug use. The AFFIRM protocol instructed
the investigators to exercise particular caution in the admin-
istration of all drugs to patients with ischemic heart disease
and/or left ventricular dysfunction (Table 1) (11). Hospi-
talization and electrocardiographic (ECG) monitoring for
initiation of treatment was strongly encouraged for all
patients with structural heart disease. The class I-C agents,
propafenone and flecainide, were not to be given to patients
with a history of congestive heart failure or structural heart
disease (ventricular myocardial disease, left ventricular hy-
pertrophy, coronary artery disease, myocardial ischemia, or
myocardial infarction). Patients who had previously experi-
enced serious ventricular arrhythmias (ventricular tachycar-
dia or ventricular fibrillation) were not eligible to receive
class I-A agents or sotalol (11,12). Dofetilide was not
approved for use by the U.S. Food and Drug Administra-
tion until near the end of the study; therefore, it was not
included in the randomization scheme for this substudy.
Follow-up. Patients were followed at 2, 4, 8, and 12
months, and at 4-month intervals thereafter, the standard
follow-up intervals for the main AFFIRM study. Although
the primary end point of the First Antiarrhythmic Drug
Substudy was measured at one year, follow-up for secondary
end points and for the main study occurred at 4-month
intervals until the end of the study—October 31, 2001.
Electrocardiograms were obtained at 4 and 12 months, per
protocol, or as clinically necessary, and the known or
estimated date of the first recurrence of AF was recorded.
End points. The primary end point of this substudy was
the percentage of patients at one year who were still alive,
were taking the assigned drug, had not had external or
internal electrical cardioversion or pharmacologic cardiover-
sion (either a new drug or augmented doses of the drug
administered long term), and were in sinus rhythm.
A secondary end point was the time to the first docu-
mented recurrence of AF, as determined by the patient
presenting with symptoms and with confirmation of AF by
electrocardiography or on routine electrocardiography at
four months and one year. Another secondary end point was
the prevalence of AF at four months and one year, as
determined by a routine ECG taken at these time intervals.
In addition, cardioversions were noted. Important descrip-
tive end points were mortality, drug tolerance, and safety.
Statistical methods. Randomization was stratified only by
clinical site. All analyses were based on the intention-to-
treat principle. Having to discontinue an assigned drug for
any reason was considered to be a drug failure, and that
patient would be counted as a failure in the arm to which he
or she had been randomized. Patients were censored at last
contact, at last vital status determination, or at withdrawal
from the study. Covariates were compared in each group by
chi-square tests, t tests, and nonparametric tests, without
adjustments for multiple comparisons. Event rates and
time-to-event curves were estimated by the Kaplan-Meier
method (14) and compared using the log-rank test.
Data were reviewed every six months by the AFFIRM
Data and Safety Monitoring Board, using the sequential
monitoring technique of O’Brien and Fleming (15) and Lan
and DeMets–type spending function (16). An alpha level of
0.0167 was used as a Bonferroni correction for the three
comparisons (17). Success in maintaining sinus rhythm, as
well as drug safety and adverse effects, was considered by the
Board in deciding whether or not to terminate the substudy.
Although some portions of the substudy were terminated
early, this analysis includes all accumulated data on random-
ized patients.
Table 2. Randomization Scheme: Numbers Eligible for Treatment Arms
Randomization
Amiodarone
Plus Class I
(n  49)
Amiodarone
Plus Sotalol
(n  95)
Sotalol Plus
Class I
(n  15)
Amiodarone, Sotalol,
and Class I
(n  251)
Total
(n  410)
Amiodarone 23 48 0 83 154
Class I 26 0 5 90 121
Sotalol 0 47 10 78 135
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RESULTS
This substudy began simultaneously with enrollment for the
main AFFIRM study in November 1995 and enrolled a
total of 410 patients, 20% of the subjects enrolled in the
rhythm control arm of the main study (Tables 2 and 3). The
randomization between amiodarone and class I drugs was
halted at the third interim analysis on December 17, 1998,
because the findings in this portion of the substudy were
considered conclusive. Furthermore, because the Data and
Safety Monitoring Board concluded that too few patients
would then be eligible for the comparison between sotalol
and class I agents, and accumulated data suggested that
continuation of this comparison could not yield a significant
result, randomization in this arm of the substudy was also
terminated. The amiodarone versus sotalol randomization
continued until the completion of AFFIRM enrollment on
October 31, 1999. The Data and Safety Monitoring Board
concluded at the seventh interim analysis on December 6,
2000, that data from this portion of the substudy were also
conclusive.
At one year, only three patients in the substudy had
withdrawn consent to participate (one assigned to amioda-
rone and two assigned to class I agents), and three patients
were lost to follow-up (all in the sotalol assignment). These
patients were censored at the time of withdrawal or loss to
follow-up.
The time to achievement of sinus rhythm after random-
ization to the rhythm control arm of the study was not
different in all three arms of this substudy. At randomiza-
tion, 46% of patients randomized to amiodarone were in
sinus rhythm, compared with 37% of patients randomized
to class I agents and 37% of patients randomized to sotalol.
Approximately 78% of all patients had sinus rhythm re-
stored by 30 days after randomization, and 92% by 120 days
after randomization.
Patient characteristics. Mean follow-up was 3.84  1.30
years. Patients enrolled in the First Antiarrhythmic Drug
Substudy were similar to the 4,060 patients enrolled in the
AFFIRM study in general, and they were also similar to
the 2,033 patients randomized to the rhythm control arm of
the main AFFIRM study (12,13). Few significant or im-
portant differences existed between the comparison groups
(Table 4).
Quinidine, propafenone, and procainamide were the
most common choices for patients randomized to the class
I arm (Tables 5 and 7).
Major end points. The primary and major end points are
summarized in Tables 5 through 7. Only p values for the
primary end point were adjusted for multiple comparisons.
For deaths, the p value is based on the Kaplan-Meier
estimates of the death rates at five years, as well as the
log-rank statistic.
At one year, successful treatment was noted in 62% of
amiodarone-treated patients, compared with 23% of pa-
tients given class I agents (p 0.001). Also at one year, 60%
of amiodarone-assigned patients were successfully treated,
compared with 38% of patients assigned to sotalol (p 
0.002). No differences were noted in the success of sotalol
compared with class I agents, with one-year point estimates
of the major end point of 34% and 23%, respectively (p 
0.488). However, as noted previously, this portion of the
substudy was stopped early, and the reduced sample size did
not provide adequate power to detect a clinically meaningful
difference.
The prevalence of AF at four months and one year was
assessed by the rhythm recorded on the ECG at those
intervals and did not take into account any other factors in
the follow-up of these patients. The prevalence of AF was
lower for amiodarone-treated patients than for class
I-treated and sotalol-treated patients at these times.
In addition, time-to-event analyses based solely on the
first recurrence of AF are illustrated in Figures 1 through 3.
In these figures, patients are censored at death, loss to
follow-up, or patient withdrawal from further participation
in the entire study. Because this analysis considers results
over time, and the primary analysis considers the data at one
year only, the percentage without recurrence in these figures
would be expected to be different from the estimates of the
primary end point and prevalences of sinus rhythm listed in
Tables 5 through 7. Amiodarone was more successful than
class I agents in preventing a recurrence of AF (p 0.0114)
(Fig. 1). Amiodarone was also more successful than sotalol
in maintaining sinus rhythm (p  0.0003) (Fig. 2). No
significant differences were noted in the ability of sotalol
versus class I agents to maintain sinus rhythm (p  0.8671)
(Fig. 3).
Multivariate analyses were performed on the two two-
way comparisons with adequate power for such an assess-
ment, evaluating for the presence of the primary end point
(death, recurrent AF, having cardioversion, or stopping the
first assigned drug). For amiodarone versus class I drugs, the
drug therapy was significant (p  0.001), and a history of
thyroid disease was associated with the primary end point (p
 0.021). For amiodarone versus sotalol, the drug therapy
was significant (p  0.003), and enrolling with a first
episode of AF (p  0.019) or having a history of thyroid
disease (p  0.048) was associated with the primary end
point.
Figure 4 shows that nearly 80% of patients were in sinus
rhythm at one-year follow-up, irrespective of the initial
randomized therapy. This result was obtained by electrical
or pharmacologic cardioversions, by changing drugs, or
Table 3. Randomization Scheme: Totals Used for Comparison
Randomization
Amiodarone
Versus Class I
Amiodarone
Versus Sotalol
Sotalol
Versus Class I
Amiodarone 23  83  106 48  83  131 0
Class I 26  90  116 0 5  90  95
Sotalol 0 47  78  125 10  78  88
Total 222 256 183
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both, for those patients whose AF recurred. Patients in the
amiodarone arms were less likely to require cardioversion or
drug changes.
This substudy was not designed to have sufficient statis-
tical power for the detection of any differences in death rates
among the different drug groups. However, we observed
that more deaths occurred in patients randomized to class I
agents than to amiodarone (Table 5). Most of these deaths
occurred during two to five years of follow-up, after the
randomized therapy had been changed. Assignment of the
cause of death can be difficult (18). Nevertheless, in this
amiodarone versus class I comparison, 26 deaths occurred in
the class I arm (7 were classified as arrhythmic deaths); 24
of these deaths occurred after the assigned drug had been
discontinued (usually for inefficacy). Of the 10 deaths in the
amiodarone arm of this comparison, four were arrhythmic
and five occurred after amiodarone was discontinued. None
were due to amiodarone-induced pulmonary toxicity. No
significant differences were noted in the death rates between
amiodarone and sotalol (15 vs. 24) (Table 6) or between
sotalol and class I agents (13 vs. 17) (Table 7), and again,
most of these deaths also occurred after the initially assigned
drug was changed or all antiarrhythmic drugs had been
discontinued. In total, 69 deaths were noted in this substudy
(11 in the first year). At the time of death, the number of
patients taking no antiarrhythmic drugs was 27, amiodarone
24, quinidine 1, disopyramide 1, flecainide 2, moricizine 1,
procainamide 3, propafenone 2, and sotalol 8.
Other end points and adverse effects. Electrical cardio-
versions in follow-up were recorded as a part of the
Table 4. Baseline Patient Demographics
Amio vs. Class I* Amio vs. Sotalol* Sotalol vs. Class I*
Amio
(n  106)
Class I
(n  116)
Amio
(n  131)
Sotalol
(n  125)
Sotalol
(n  88)
Class I
(n  95)
Age (yrs) 67.7  9.6† 70.1  7.8† 67.9  8.5† 70.4  8.9† 70.6  8.5 69.5  8.0
Male 69 (65.1) 69 (59.5) 86 (65.6) 79 (63.2) 54 (61.4) 59 (62.1)
Primary cardiac diagnosis
CAD 26 (24.5) 23 (19.8) 36 (27.5) 25 (20.0) 19 (21.6) 16 (16.8)
CM 6 (5.7) 4 (3.4) 7 (5.3) 7 (5.6) 3 (3.4) 4 (4.2)
HTN 51 (48.1) 61 (52.6) 65 (49.6) 66 (52.8) 46 (52.3) 51 (53.7)
Other 7 (6.6) 7 (6.0) 8 (6.1) 9 (7.2) 6 (6.8) 7 (7.4)
None (“lone” AF) 16 (15.1) 21 (18.1) 15 (11.5) 18 (14.4) 14 (15.9) 17 (17.9)
History
CHF 18 (17.0) 25 (21.6) 20 (15.3)† 32 (25.6)† 18 (20.5) 17 (17.9)
Angina‡ 27 (25.5) 22 (19.0) 36 (27.5) 30 (24.0) 20 (22.7) 12 (12.6)
MI 16 (15.1) 14 (12.1) 25 (19.1) 18 (14.4) 9 (10.2) 8 (8.4)
Duration of qualifying AF episode
48 h 31 (29.2) 35 (30.2) 40 (30.5) 33 (26.4) 27 (30.7) 31 (32.6)
48 h 75 (70.8) 81 (69.8) 91 (69.5) 92 (73.6) 61 (69.3) 64 (67.4)
First episode of AF 25 (26.9) 41 (38.7) 33 (28.0)† 50 (42.7)† 31 (37.8) 36 (41.9)
Previous drug failures 19 (17.9) 25 (21.6) 22 (16.8) 15 (12.0) 10 (11.4) 18 (18.9)
AF episodes more than once per week 18 (23.7) 24 (33.8) 20 (21.5) 19 (26.4) 11 (20.4) 20 (36.4)
LA size§
Normal 25 (27.5) 32 (30.5) 31 (28.4) 32 (28.6) 25 (32.1) 27 (31.0)
Mild enlargement 28 (30.8) 30 (28.6) 36 (33.0) 20 (17.9) 14 (17.9) 21 (24.1)
Moderate to severe enlargement 33 (36.3) 36 (34.3) 35 (32.1) 50 (44.6) 33 (42.3) 33 (37.9)
Unknown 5 (5.5) 7 (6.7) 7 (6.4) 10 (8.9) 6 (7.7) 6 (6.9)
LVEF¶
Normal 67 (72.8) 72 (68.6) 80 (72.7) 78 (69.6) 59 (75.6) 61 (70.1)
Mild dysfunction 6 (6.5) 8 (7.6) 8 (7.3) 12 (10.7) 7 (9.0) 6 (6.9)
Moderate dysfunction 5 (5.4) 9 (8.6) 8 (7.3) 8 (7.1) 1 (1.3) 7 (8.0)
Severe dysfunction 5 (5.4) 4 (3.8) 3 (2.7) 1 (0.9) 1 (1.3) 3 (3.4)
Unknown 9 (9.8) 12 (11.4) 11 (10.0) 13 (11.6) 10 (12.8) 10 (11.5)
Initial other cardiovascular drugs
Beta-blockers 27 (26.5) 33 (30.3) 36 (28.3)† 21 (17.4)† 12 (14.3)† 31 (35.2)†
Calcium channel blockers 31 (30.4) 39 (35.8) 40 (31.5)† 17 (14.0)† 13 (15.5)† 28 (31.8)†
ACE inhibitors 33 (32.4) 49 (45.0) 45 (35.4) 45 (37.2) 32 (38.1) 40 (45.5)
*Includes patients eligible for both drugs who were randomized to one of them. For example, a patient who was eligible for all three drugs and was randomized to amiodarone
is included in the amio vs. class I and amio vs. sotalol columns. However, if the patient was not eligible to receive sotalol, he or she would be included only in the amio vs. class
I comparison. †Unadjusted p  0.05 (comparison within each randomization group, i.e., p value for amio vs. class I, amio vs. sotalol, or sotalol vs. class I). ‡Patients could be
reported as having angina even though the primary diagnosis was not CAD. §Normal  4.0 cm; mild enlargement  4.1–4.5 cm; moderate to severe enlargement  4.5
cm. ¶Normal0.50; mild dysfunction 0.40–0.49; moderate dysfunction 0.30–0.39; severe dysfunction0.30. Data are presented as the mean value SD or number
(%) of patients. Percentages reflect patients for whom data were available, making denominators smaller than the total number for each column.
ACE  angiotensin-converting enzyme; AF  atrial fibrillation; Amio  amiodarone; CM  cardiomyopathy; HTN  hypertension; LA  left atrium; MI  myocardial
infarction; other abbreviations as in Table 1.
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AFFIRM protocol. By one year, 29% of patients random-
ized to amiodarone, 33% of patients randomized to sotalol,
and 36% of patients randomized to class I agents had been
cardioverted (p  0.52).
Only one case of torsade de pointes ventricular tachycar-
dia was recognized in this substudy population (in a patient
taking quinidine for more than one year). Furthermore, no
cases of agranulocytosis or lupus syndrome induced by
procainamide were reported in these substudy patients.
Adverse effects causing discontinuation of the antiarrhyth-
mic drugs during the first year were frequent (Table 8),
occurring in 12.3% of patients taking amiodarone, 11.1%
taking sotalol, and 28.1% taking class I agents. Among
those patients randomized to amiodarone, pulmonary tox-
icity was diagnosed in two patients (1.3%) by one year, three
patients (2.0%) by two years, and no additional patients by
three years. Gastrointestinal adverse events were a common
reason for stopping class I drugs.
DISCUSSION
This study is a prospective, randomized comparison of the
efficacy and safety of antiarrhythmic agents available for the
suppression of AF. On the basis of the primary substudy
end point, amiodarone was better than either sotalol or class
I agents in separate comparisons. Serious adverse drug
effects were uncommon within the one-year time frame of
the primary end point in this AFFIRM substudy, although
adverse effects that led to discontinuation of a drug were
frequent.
The baseline clinical characteristics of this population,
including the duration of the qualifying episode of AF, the
extent of left ventricular dysfunction, and the size of the left
atrium, gave them not only a high risk for stroke and death
but also a high risk for recurrence of AF. All patients in the
antiarrhythmic drug group comparisons had similar clinical
characteristics, except for minor imbalances in age, history
of congestive heart failure, proportion of patients presenting
with a first episode of AF, and beta-blocker and calcium
channel blocker use. Given the large number of comparisons
tested, it would be expected that some would be significant
simply by chance.
Measures of antiarrhythmic drug efficacy. Antiarrhyth-
mic drugs are frequently compared for their ability to
maintain sinus rhythm. In general, most antiarrhythmic
Table 5. First Antiarrhythmic Drug Substudy End Points: Amiodarone Versus Class I Drugs*
Amiodarone
(n  106)
Class I Agent
(n  116)
Unadjusted
p Value
Prevalence of AF
4 months† 11/87 (13%) 29/103 (28%) 0.009
1 year† 6/75 (8%) 13/72 (18%) 0.069
Composite end point: patients
alive, on drug, in sinus
rhythm, no cardioversions
4 months† 59/86 (69%) 35/101 (35%)  0.001
1 year (primary end point)† 46/74 (62%) 17/74 (23%)  0.001‡
Deaths (no. of arrhythmic deaths) 10 (4) 26 (7) 0.008 (0.391)§
*Number of patients initially taking each drug: amiodarone (n  105) or none (n  1) versus class I agents—quinidine (n 
29), procainamide (n  24), disopyramide (n  12), moricizine (n  4), propafenone (n  31), flecainide (n  7), none (n 
11) (the sum of class I drugs is 116 because some patients tried more than one drug during the initiation of therapy). †The
denominators at 4 months and 1 year do not equal the total numbers of patients because of incomplete data acquisition at that
time point. ‡Adjusted for multiple comparisons, but unadjusted for group sequential monitoring; comparison terminated at the
third interim analysis due to a significant result. §Rates estimated by Kaplan-Meier analysis at 5 years and compared using the
log-rank statistic. Some patients did not immediately start the assigned drug.
AF  atrial fibrillation.
Table 6. First Antiarrhythmic Drug Substudy End Points: Amiodarone Versus Sotalol*
Amiodarone
(n  131)
Sotalol
(n  125)
Unadjusted
p Value
Prevalence of AF
4 months† 22/126 (17%) 27/122 (22%) 0.356
1 year† 15/123 (12%) 22/115 (19%) 0.140
Composite end point: patients
alive, on drug, in sinus
rhythm, no cardioversions
4 months† 84/125 (67%) 58/121 (48%) 0.002
1 year (primary end point)† 73/121 (60%) 44/115 (38%) 0.002‡
Deaths (no. of arrhythmic deaths) 15 (5) 24 (5) 0.081 (0.900)§
*Number of patients initially taking each drug: amiodarone (n  130) or none (n  1) versus sotalol (n  114) or none (n 
11). †The denominators at 4 months and 1 year do not equal the total numbers of patients because of incomplete data acquisition
at that time point. ‡Adjusted for multiple comparisons, but unadjusted for group sequential monitoring; comparison terminated
at the seventh interim analysis due to a significant result. §Rates estimated by Kaplan-Meier analysis at 5 years and compared
using the log-rank statistic. Some patients did not immediately start the assigned drug.
AF  atrial fibrillation.
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drugs are able to maintain sinus rhythm in only 50% of
patients at one year. For amiodarone, this percentage
appears to be greater (19). However, this AFFIRM sub-
study had a complex composite end point that incorporated
survival, adverse effects that required discontinuation of the
drug, and the ability to control cardiac rhythm without
cardioversion. Although the results of this substudy are
clear, it is not necessarily true that a single recurrence of AF
should be called a categorical failure of an antiarrhythmic
drug. The choice of an antiarrhythmic drug to suppress AF
is sufficiently complex such that no single measure of efficacy
or adverse effects can be used alone to determine optimal
therapy. For instance, although amiodarone was the drug
most likely to maintain sinus rhythm without cardioversion,
its potential for serious adverse effects over a long term
might preclude it being used as the first drug. Moreover, it
might be preferable to accept an occasional recurrence of
AF using a drug with easily reversible potential adverse
effects than to use a drug with less likelihood of AF
recurrence but with potential adverse effects that occur late
and recede slowly. As demonstrated by this substudy,
starting with an antiarrhythmic drug other than amiodarone
and accepting serial therapy (cardioversion to restore sinus
rhythm if needed and possibly switching to another antiar-
rhythmic drug) will result in sinus rhythm being present at
one year in nearly 80% of patients. In short, when choosing
a drug, there should be a balance between potential adverse
effects and potential beneficial effects of maintaining sinus
rhythm, and the frequency of AF recurrence must be
considered.
Substudy deaths. Of note, deaths most often occurred
after the one-year primary end point of this substudy was
assessed, usually after drug therapy had been stopped or
changed. Although the higher mortality rate in patients
starting with class I drugs is intriguing, it is unexplained.
Most of these deaths occurred after the class I drug was
discontinued (for inefficacy or adverse effects) and while
another drug, often amiodarone, was being used.
Comparison with other studies. Our substudy population
was larger than most previous studies. Its patients were
Table 7. First Antiarrhythmic Drug Substudy End Points: Sotalol Versus Class I Drugs*
Sotalol
(n  88)
Class I
(n  95)
Unadjusted
p Value
Prevalence of AF
4 months† 17/77 (22%) 24/83 (29%) 0.322
1 year† 12/63 (19%) 13/61 (21%) 0.753
Composite end point: patients
alive, on drug, in sinus
rhythm, no cardioversions
4 months† 35/76 (46%) 28/80 (35%) 0.160
1 year (primary end point)† 21/62 (34%) 14/62 (23%) 0.488‡
Deaths (no. of arrhythmic deaths) 13 (2) 17 (5) 0.494 (0.294)§
*Number of patients initially taking each drug‡: sotalol (n  79) or none (n  9) versus class I drugs—quinidine (n  25),
procainamide (n  20), disopyramide (n  11), moricizine (n  2), propafenone (n  23), flecainide (n  9), none (n  8)
(the sum of class I drugs is95 because some patients tried more than one drug during initiation of therapy). †The denominators
at 4 months and 1 year do not equal the total numbers of patients because of incomplete data acquisition at that time point.
‡Adjusted for multiple comparisons, but unadjusted for group sequential monitoring; comparison terminated at the third interim
analysis due to superiority of amiodarone over class I agents. §Rates estimated by Kaplan-Meier analysis at 5 years and compared
using the log-rank statistic. Some patients did not immediately start the assigned drug.
AF  atrial fibrillation.
Figure 1. Time to recurrence of atrial fibrillation—amiodarone versus class I drugs. Time zero is the first day sinus rhythm was documented. Patients were
censored at death, if lost to follow-up, or upon withdrawal of consent.
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better characterized and had a higher risk for recurrence and
adverse outcomes, such as stroke and death. Also, although
other studies have usually compared one drug with placebo
or one drug with another, this substudy was unique in
evaluating multiple, randomly selected drugs to maintain
sinus rhythm.
This AFFIRM substudy generally confirms the results of
previous studies of the efficacy of antiarrhythmic drugs to
maintain sinus rhythm. The Canadian Trial of Atrial
Fibrillation (CTAF) investigators compared amiodarone
with sotalol and propafenone for the maintenance of sinus
rhythm in patients with a history of AF (19). The primary
end point was the first recurrence of AF, as measured by
transtelephonic monitoring. The mean follow-up period
was 16 months. They showed that 69% of patients main-
tained sinus rhythm at one year with amiodarone, and
amiodarone was superior to sotalol or propafenone for the
maintenance of sinus rhythm in these patients.
The Pharmacological Intervention in Atrial Fibrilla-
tion (PIAF) study compared rate control with rhythm
control in patients with a history of AF (20). It demon-
strated that sinus rhythm could be maintained with
amiodarone in 56% of patients at one year. The PIAF
study had a one-year follow-up period, with the primary
end point being improvement of symptoms. Symptomatic
improvement was similar in the rate control and rhythm
control groups.
In PIAF, 25% of patients had stopped amiodarone at one
year because of adverse effects (20). Pulmonary toxicity was
not reported. In CTAF (with a follow-up of 16 months,
slightly longer than that in PIAF), 18% of patients stopped
amiodarone because of adverse events. Pulmonary toxicity
was suspected in five patients (2.5%), although no deaths
from pulmonary toxicity were noted (19). These results were
similar to the experience in the AFFIRM substudy, with 3.8
years of mean follow-up.
Figure 2. Time to recurrence of atrial fibrillation—amiodarone versus sotalol. Time zero is the first day sinus rhythm was documented. Patients were
censored at death, if lost to follow-up, or upon withdrawal of consent.
Figure 3. Time to recurrence of atrial fibrillation—sotalol versus class I drugs. Time zero is the first day sinus rhythm was documented. Patients were
censored at death, if lost to follow-up, or upon withdrawal of consent.
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Study limitations. The primary end point measured at one
year might not, by itself, be the only appropriate criterion to
evaluate antiarrhythmic drug therapy. Most patients with
AF will require therapy for many years, even decades, and
thus would be subject to longer term potential adverse
effects of the drugs. It is possible that this “early” end point
biases our results toward amiodarone, for which longer term
adverse effects are a concern. However, it is one reasonable
measure of drug effectiveness.
Not all antiarrhythmic drugs were tested in the AFFIRM
substudy, nor were those tested used equally. Furthermore,
class I drugs were considered as a group for purposes of the
substudy, but they are not interchangeable.
Drug administration was not blinded, and adverse event
reporting could have been biased.
The substudy required that a patient be able to take at
least two rhythm control drugs. It is possible that efficacy
would have been higher and toxicity lower for one or more
drugs in a younger, healthier group—for example, patients
with “lone” fibrillation and no risk factors for stroke, who
were not eligible for AFFIRM.
It is difficult to know whether the doses administered of
the different drugs were comparable across all patients to
whom they were given. Written guidelines for dosing were
part of the AFFIRM protocol, and they were adjusted
within the limits of clinical judgment and patient tolerance.
Thus, our results likely reflect what most experienced
physicians would do in clinical practice. Furthermore, newer
antiarrhythmic drugs, such as dofetilide, were not tested in
this protocol.
Episodes of paroxysmal AF are frequently asymptomatic,
even in patients who have some symptomatic episodes.
Thus, a patient with sinus rhythm at one-year follow-up
might be having asymptomatic recurrences that are unde-
tected. Clinically, this phenomenon could be dangerous,
especially if warfarin had been discontinued because it was
thought that the patient had achieved successful rhythm
control. This scenario may be particularly common with
those antiarrhythmic drugs that also slow the ventricular
rate during a recurrence of AF.
Accepted definitions for the three types of AF (paroxys-
mal, persistent, and permanent) (21) had not been articu-
lated when this trial was in its planning stages (1). Thus,
patients were not classified by this scheme. Our approxima-
tion that classified patients by the duration of known AF
(48 h or 48 h) of the qualifying episode is not precisely
the same.
Conclusions. This AFFIRM substudy should be viewed in
the context of the main AFFIRM results, which support
rate control as an acceptable primary treatment. Among
patients eligible to participate in AFFIRM in whom rhythm
control drugs were randomly assigned, amiodarone was
better than class I agents and sotalol for the maintenance of
sinus rhythm at one year, defined as the patient being alive,
still taking the drug, being in sinus rhythm, and needing no
electrical cardioversions.
If amiodarone is not chosen as the primary antiarrhyth-
mic drug, the use of another antiarrhythmic drug alone will
yield about a 20% to 40% prevalence of sinus rhythm at one
year without cardioversion. Sequential treatment with two
or more antiarrhythmic drugs, with or without cardioversion,
can achieve nearly 80% prevalence of sinus rhythm at one year.
Figure 4. Prevalence of sinus rhythm (SR) at one year. Patients are
included only if they were randomized one year or more before the
termination of the substudy. Black bars  SR, another drug,  cardio-
version; hatched bars  SR, on drug #1, cardioversion; white bars  SR,
on drug #1, no cardioversion.
Table 8. Adverse Effects Causing Discontinuation of First Antiarrhythmic Drug Within the
First Year
Amiodarone
(n  154)
Sotalol
(n  135)
Class I
(n  121)
Torsade de pointes ventricular tachycardia 0 0 0
Congestive heart failure 0 3 (2.2%) 2 (1.7%)
Pulmonary events* 4 (2.6%) 1 (0.7%) 1 (0.8%)
Gastrointestinal events 4 (2.6%) 6 (4.4%) 14 (11.6%)
Symptomatic bradycardia 0 3 (2.2%) 4 (3.3%)
Prolonged QTc (520 ms) 0 0 5 (4.1%)
Syncope 0 1 (0.7%) 3 (2.5%)
Ocular effects 1 (0.6%) 0 1 (0.8%)
Other 11 (7.1%) 7 (5.2%) 17 (14.0%)
*“Pulmonary events” causing at least transient discontinuation of a drug. Only two of the four pulmonary events reported for
amiodarone were ultimately diagnosed as pulmonary toxicity. Events reported are on therapy within one year of follow-up.
Percentages are calculated based on the number of patients with complete data reported at one year. Some patients had more
than one reason for drug discontinuation, and some drugs were stopped for inefficacy, unreported adverse effects, or other reasons.
QTc  corrected QT interval.
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The adverse effects of all drugs tested in this protocol
were common over the first year.
If the rhythm control strategy is chosen for any given
patient, antiarrhythmic drug treatment must remain indi-
vidualized, considering any underlying disease, potential
drug efficacy, and the potential risk of short-term and
long-term exposure to that drug.
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